

Additional file 3: Comparison of study participants and non-responders regarding the chance for study participation: results from multilevel logistic regression analysis allowing for random effects at the study centre and GP practice-within-study centre level

	Participants (n=3,189)	Non-responders (n=3,855)	Risk ratio [95% CI]	p*
Gender: male	40.7%	35.1% [n=3,850]	1,16 [1,09-1,24]	< 0.001
<i>Age < 75 when contacted for informed consent</i>	<i>55.5%</i>	<i>44.3% [n=3,526]</i>	<i>1,26 [1,21-1,31]</i>	<i>< 0.001</i>
Diagnosis groups used for patient inclusion				
- Joint arthrosis	38.1%	35.7%	1,13 [1,06-1,20]	< 0.001
- Diabetes mellitus	36.9%	40.1%	0,92 [0,86-0,99]	0.017
- Thyroid dysfunction	32.4%	31.5%	1,09 [1,01-1,17]	0.031
- Chronic ischemic heart disease	30.9%	30.3%	1,03 [0,95-1,11]	0.475
- Cardiac arrhythmias	26.2%	24.3%	1,10 [1,00-1,19]	0.039
- Asthma/COPD	24.3%	23.4%	1,05 [0,96-1,15]	0.261
- Cancers	21.8%	19.6%	1,10 [0,99-1,21]	0.065
- Lower limb varicosis	21.7%	22.7%	0,95 [0,86-1,05]	0.338
- Osteoporosis	19.0%	17.9%	1,17 [1,05-1,30]	0.005
- Atherosclerosis/PAOD	17.7%	16.4%	1,01 [0,90-1,13]	0.882
- Severe vision reduction	16.4%	15.9%	1,08 [0,96-1,21]	0.213
- Depression	15.3%	17.4%	0,93 [0,83-1,05]	0.238
- Neuropathies	14.8%	13.8%	1,13 [1,00-1,28]	0.055
- (Alcoholic) liver diseases and alcohol abuse	13.1%	14.4%	0,83 [0,72-0,95]	0.006
- <i>Intestinal diverticulosis</i>	<i>12.3%</i>	<i>8.5%</i>	<i>1,39 [1,20-1,60]</i>	<i>< 0.001</i>
- Cardiac insufficiency	10.6%	11.5%	0,96 [0,83-1,11]	0.611
- Cerebral ischemia/Chronic stroke	10.4%	9.7%	1,07 [0,92-1,25]	0.362
- Renal insufficiency	9.6%	9.1%	1,05 [0,89-1,23]	0.554
- Cardiac valve disorders	8.8%	7.2%	1,18 [0,99-1,39]	0.064
- Urinary incontinence	6.0%	6.0%	1,14 [0,93-1,39]	0.196
- Somatoform disorders	5.9%	6.3%	0,90 [0,73-1,10]	0.292
- Dizziness	5.6%	5.7%	1,03 [0,83-1,26]	0.802
- Severe hearing loss	5.1%	5.0%	0,99 [0,79-1,23]	0.902
- Anemias	4.9%	4.9%	1,04 [0,83-1,29]	0.762
- Anxiety	4.1%	4.4%	0,89 [0,69-1,13]	0.337
- Migraine	3.7%	3.8%	0,98 [0,76-1,27]	0.905
- <i>Psoriasis</i>	<i>3.7%</i>	<i>2.7%</i>	<i>1,35 [1,03-1,77]</i>	<i>0.031</i>
- Rheumatoid arthritis/Chronic polyarthritis	3.5%	3.6%	1,00 [0,77-1,30]	0.984
- Parkinson's disease	1.9%	1.4%	1,40 [0,95-2,05]	0.088

n: number of observations; 95% CI: 95% confidence interval; * statistically significant ($p \leq 0.05$) and clinically relevant results ($RR \leq 0.75$ and ≥ 1.25 , respectively) in italic and bold letters.